These findings indicate a new role of AR in HER2 signaling, and anti-AR target therapy may be beneficial in HER2+ BC patients that are unresponsive or that develop resistance to anti-HER2 therapies [56]. This evidence concerns the gene ERBB2 and breast cancer.